Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8612124 | 0.91 | ILK (0.84) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL9104641 | 0.89 | ILK (0.80) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL9103873 | 0.89 | ILK (0.80) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL9102839 | 0.86 | ILK (0.76) | ILKRXRARXRBRXRGMAPKAPK2 | |
| SCHEMBL17077247 | 0.86 | ILK (0.75) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL17087637 | 0.85 | ILK (0.74) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL15560693 | 0.85 | ILK (0.74) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL29694581 | 0.85 | ILK (0.73) | ILKP2RY14MAPKAPK2MAOBPTGS2 | |
| SCHEMBL17077245 | 0.83 | ILK (0.70) | ILKALOX5RXRARXRBRXRG | |
| SCHEMBL17087661 | 0.82 | ILK (0.70) | ILKALOX5RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025053613-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL NERVE TUMOR COMPRISING ILK INHIBITOR AND USE THEREOF | 재단법인 아산사회복지재단 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2023-04-27 | — | — | US | disclosed |
| US-11524945-B2 | Compounds for treating ILK-mediated diseases | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-12-13 | — | — | US | disclosed |
| CN-114617886-A | Antibacterial use of compounds and pharmaceutically acceptable salts thereof | 中国医学科学院医药生物技术研究所 | 2022-06-14 | — | — | CN | disclosed |
| US-20210114993-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | THE CLEVELAND CLINIC FOUNDATION | 2021-04-22 | — | — | US | disclosed |
| EP-2642856-B1 | INTEGRIN-LINKED KINASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8658647-B2 | Integrin-linked kinase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2642856-A1 | INTEGRIN-LINKED KINASE INHIBITORS | The Ohio State University Research Foundation (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-103298344-A | Integrin-linked kinase inhibitors | UNIV OHIO STATE RES FOUND | 2013-09-11 | — | — | CN | disclosed |
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012071310-A1 | INTEGRIN-LINKED KINASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114993-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | ILK, ITGB1, ITGA2B | ILK 1/4885ALOX5 3182/4885RXRA 2980/4885 |
| US-20230127636-A1 | COMPOUNDS FOR TREATING ILK-MEDIATED DISEASES | ILK, ITGB1, ITGA2B | ILK 1/4885ALOX5 3182/4885RXRA 2980/4885 |
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | PTK2, ITGB1, ITGB2 | ILK 8/4885ALOX5 3094/4885RXRA 3080/4885 |
| US-11524945-B2 | Compounds for treating ILK-mediated diseases | ILK, ITGB1, ITGA2B | ILK 1/4885ALOX5 3182/4885RXRA 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.